Skip to main content

Cardiac Pacemakers

An overview of market access challenges for cardiac pacemaker implantation in European countries.

dcv

Procedure coding

Procedure coding is well-established for cardiac pacemakers in European countries. Implantation, replacement, and removal of cardiac pacemakers are typically coded separately. 

In many countries, the procedure codes for cardiac pacemaker implantation differ depending on its type (single-chamber, dual-chamber, leadless).

For example, in England, there are specific OPCS codes for transvenous implantation (code K60.5 – for single chamber cardiac pacemaker system, code K60.6 – for dual chamber cardiac pacemaker system), renewal (code K73.1 – for single chamber cardiac pacemaker system, code K73.2 – for dual chamber cardiac pacemaker system) and removal of intravenous cardiac pacemaker system (code K60.4). The procedures related to the epicardial pacemaker system are coded separately.

sdfv

Payment mechanism

The payment model for cardiac pacemaker implantation or replacement is DRG in most European countries.

In some countries, the DRG allocation depends on the type of pacemaker (e.g., Austria, England, or Switzerland). In other countries, the clinical indication impacts the DRG allocation (e.g., Denmark, France). For example, in Germany, implantation of a single-chamber cardiac pacemaker is reimbursed via DRG F17B “Replacement of cardiac pacemaker, single-chamber system” with a tariff of €18,087. In contrast, implantation of a dual-chamber pacemaker is allocated to the DRG F17A “Replacement of cardiac pacemaker, multi-chamber system” with a higher tariff of €21,946.

In most European countries, cardiac pacemakers do not attract additional (top-up) reimbursement, which is paid in addition to the DRG tariff. One exception is England, where the intracardiac pacemaker system and wireless pacemakers are included in the High Cost Devices List and reimbursed in addition to the HRG tariff.

cvbgf

Policy considerations

As cardiac pacemaker implantation and replacement procedures are well-established technologies, they are unlikely to be subject to specific policies from payers or national decision-makers in the countries where such frameworks exist.

efdvfb

Health technology assessment

Due to established reimbursement in European countries, cardiac pacemakers rarely become a subject of HTA. 

wedfbgn

Future challenges 

Implementing cardiac pacemakers has established reimbursement and funding in most European countries. New health technology assessments are unlikely to be relevant. It is unlikely to benefit from the innovative payment schemes. 

Novel cardiac pacemakers with unique designs or alternative stimulation modes might need to develop specific procedure codes and adjust payment mechanisms to fully leverage their unique technology or cost profile. 

MTRC has experience with more than 7 projects related to cardiac pacemakers in Europe

News and insights

February 2026 recommendations about add-on reimbursement for medical devices in France

The French National Authority for Health (HAS) released new recommendations on the registration of medical devices and medical aids in the List of Reimbursable Products and Services (LPPR) following the February 2026 meetings of the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDiMTS). Favourable opinions were issued on the add-on reimbursement for six new devices and on the extension of indications for two devices, in the cardiovascular, peripheral vascular, and ENT fields.

Med Tech-related technology assessments from NICE in February 2026

In February 2026, the National Institute for Health and Care Excellence (NICE) published three new HealthTech Guidances (HTGs) on transcatheter tricuspid valve implantation, leadless cardiac pacemakers for bradyarrhythmia, and pulmonary artery pressure technologies for remote monitoring of chronic heart failure.

Updates in the coverage of medical services in Switzerland in 2026

On December 3, 2025, the Swiss Federal Office of Public Health published updates to the Healthcare Benefit Ordinance (KLV/OPre), which determines coverage of medical services in Switzerland. The changes will take effect on January 1, 2026, and relate to prophylactic vaccinations, cost containment measures, and other matters. The updates are also implemented in KLV Annexes, including the List of explicitly evaluated services (Annex 1), the outpatient-before-inpatient mandate (Annex 1a), the List of Medical Aids (Annex 2, MiGeL), and the List of Analyses (Annex 3, AL).

Get in touch

Contact us to discuss your needs and learn about our services